BAY38-9456 - Pivotal Trial for Diabetes Patient

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
The superiority of BAY 38-9456 10 mg and 20 mg regimens to placebo, and of 20 mg to 10 mg was confirmed in patients with diabetes mellitus suffering from erectile dysfunction. There was no large difference in incidence rate of drug-related adverse events between 10 mg and 20 mg regimens. Overall the tolerability was considered good with both regimens.
Epistemonikos ID: c0d47cd66c0aae456e6eb1e0f0174415af870165
First added on: May 05, 2024